In April 2026, a Florida defense-technology startup and a university research foundation began a licensing relationship that, four months later, produced an exclusive global license for a patented drone technology. The deal is unremarkable in its broad shape — option agreement, then term sheet, then definitive license — but it is a clean, publicly documented illustration of the staged pathway most university technology transfer offices (TTOs) use to move a patent from the lab to a commercial or dual-use licensee.
What happened
NorthStrive Defense Tech LLC, a wholly owned subsidiary of Nasdaq-listed PMGC Holdings Inc., and the Florida State University Research Foundation (FSURF) — the 501(c)(3) that manages Florida State University’s intellectual property and licensing on the university’s behalf — moved through three publicly announced stages:
- April 6, 2026: the parties entered an exclusive option agreement giving NorthStrive time-limited rights to evaluate the technology before committing to a full license.
- June 8, 2026: they signed a binding term sheet setting out the commercial terms of the eventual license.
- July 13, 2026: NorthStrive executed a definitive exclusive license agreement with FSURF, converting the term sheet into a signed license covering U.S. Patent No. 12,291,334 and related know-how.
Alongside the licensing track, NorthStrive and FSURF also entered a sponsored research agreement funding continued development work at FSU intended to advance the technology toward a working prototype; that research program is described as ongoing.
The technology
The license covers what the companies describe as a multi-domain drone payload system: an aerial vehicle designed to transport a cable-suspended payload through water while the vehicle itself maintains flight above the surface, using buoyancy-assisted transport to move payloads across air and water environments. The stated target applications span defense, aerospace, and maritime use cases, with an explicit development path toward engagement with U.S. defense agencies, including the Department of Defense and the Navy.
The license is described as exclusive, worldwide, and sublicensable within the aerospace and defense technologies field — a common combination for dual-use hardware IP, where a licensee needs freedom to operate globally and the ability to bring in manufacturing or integration partners under sublicense.
Why the deal is staged this way
The three-step sequence — option, term sheet, definitive license — is not specific to this deal; it is the default risk-management structure most TTOs use for early-stage, unproven technology, particularly where a prospective licensee is a small or newly formed company rather than an established manufacturer:
- An option agreement lets the prospective licensee evaluate the technology, run technical or market diligence, and sometimes raise financing, before either side commits to full license terms. It is deliberately narrower and shorter-lived than a license.
- A term sheet is a non-binding-in-parts (but here explicitly described as “binding”) summary of the commercial terms — royalty structure, milestones, exclusivity scope — negotiated once diligence is far enough along to price the deal.
- The definitive license agreement is the fully executed contract that actually conveys rights. For guidance on what distinguishes an exclusive license from a non-exclusive one, and what each implies for the university’s ability to license the same patent elsewhere, see CASRAI’s comparison page.
Research administrators and TTO staff evaluating a similar deal will recognize this as the same sequence covered in CASRAI’s guide to the technology transfer process, from invention disclosure through licensing and revenue distribution, and in the guide on patent licensing terms for exclusive deals with early-stage companies specifically.
What it signals for university tech transfer
A few features of this deal are broadly relevant beyond the specific parties involved:
- Defense and dual-use IP licensing is an active lane for university TTOs. Patented technology developed at a university, even where the eventual application is defense-oriented, routinely moves to market through exactly this licensing structure rather than direct government contracting by the university itself.
- Licensing and sponsored research often run in parallel, not sequence. A sponsored research agreement funding further development at the university, alongside a license already granted to a company, is a common structure when the technology needs continued institutional research capacity to reach a working prototype.
- Government funding pathways remain part of the plan even after a private license is signed. The stated development plan includes submitting non-dilutive funding applications (e.g., SBIR/STTR-type federal funding) alongside private capital, which is typical for defense-adjacent hardware that needs to reach a federal customer eventually.
Any patent exclusively licensed by a university that received federal funding for the underlying research remains subject to the Bayh-Dole Act framework, including the government’s retained march-in rights and reporting obligations — see CASRAI’s guide on what march-in rights mean for university tech transfer for what that does and does not constrain for a licensee.
Frequently asked questions
What is the difference between an option agreement and a license agreement?
An option agreement gives a prospective licensee time-limited rights to evaluate a technology — reviewing data, running diligence, sometimes securing financing — before deciding whether to proceed to a full license. It does not itself convey the right to make, use, or sell the technology commercially. A license agreement is the operative contract that actually grants those rights, typically negotiated once an option holder decides to proceed. See CASRAI’s option agreement vs. license agreement comparison for the full breakdown.
What does “exclusive, worldwide, sublicensable” mean in a university license?
Exclusive means the university (through its research foundation or TLO) will not license the same patent to another party in the licensed field of use. Worldwide extends that exclusivity globally rather than to a single territory. Sublicensable means the licensee can grant its own sublicenses to third parties — useful for a small company that needs manufacturing or integration partners — typically subject to the university’s approval and a share of any sublicense revenue.
Why would a university keep researching a technology after licensing it?
A sponsored research agreement running alongside a license is common when a technology is still early-stage at the time of licensing. The licensee funds continued research at the university — often to reach a working prototype or de-risk a specific technical question — while holding commercial rights to whatever the research produces, under the terms already set in the license.
Does a private license affect the government’s rights under Bayh-Dole?
No. If the underlying invention was developed with federal funding, the university’s Bayh-Dole obligations — including retained government-use rights and, in narrow circumstances, march-in rights — attach to the patent regardless of who holds a commercial license. A university TTO cannot license around those obligations.
This page describes a specific, publicly announced licensing transaction for informational purposes as an illustration of standard university technology-transfer deal structure. It is not investment, legal, or licensing advice, and CASRAI has no relationship with either party. Readers evaluating a comparable deal should consult their own institution’s technology transfer office and counsel.
